Apharm

Apharm is an Italian healthcare company focused on the research and development of proprietary products and patented formulations that are licensed globally. The company has been particularly active in medical devices, nutraceuticals, and specialty products spanning gastroenterology, orthopedics, and dermatology. Apharm became part of the Biofarma Group after Nutrilinea acquired a majority stake in 2019, and Biofarma later acquired the remaining minority interest in 2022. Its known commercialized products include hyaluronic-acid-based intra-articular injections such as Hyalexo Mono and Hyalexo Cross, distributed through partners including Laboratoires Expanscience. Apharm appears to operate primarily as a product development and IP-driven out-licensing business rather than as a traditional clinical-stage biotech with a disclosed therapeutic pipeline.